Quantitative fluorescence imaging analysis for cancer biomarker discovery

Application to β-catenin in archived prostate specimens

Dali Huang, George P Casale, Jun Tian, Nizar K Wehbi, Neil A. Abrahams, Zahid Kaleem, Lynette M Smith, Sonny L. Johansson, Johny E. Elkahwaji, George P. Hemstreet

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

The surprising disparity between the number of protein-encoding genes (∼30,000) in the human genome and the number of proteins (∼300,000) in the human proteome has inspired the development of translational proteomics aimed at protein expression profiling of disease states. Translational proteomics, which offers the promise of early disease detection and individualized therapy, requires new methods for the analysis of clinical specimens. We have developed quantitative flourescence imaging analysis (QFIA) for accurate, reproducible quantification of proteins in slide-mounted tissues. The method has been validated for the analysis of β-catenin in archived prostate specimens fixed in formalin. QFIA takes advantage of the linearity of fluorescence antibody signaling for tissue epitope content, a feature validated for β-catenin in methacarn-fixed prostate specimens analyzed by reverse-phase protein array analysis and QFIA (r = 0.97). QFIA of β-catenin in formaldehyde-fixed tissues correlated directly with β-catenin content (r = 0.86). Application of QFIA in a cross-sectional study of biopsies from 42 prostate cancer (PC) cases and 42 matched controls identified β-catenin as a potential field marker for PC. Receiver operating characteristic plots revealed that β-catenin expression in the normal-appearing acini of cancerous glands identified 42% (95% confidence intervals, 26-57%) of cancer cases, with 88% (95% confidence intervals, 80-96%) specificity. The marker may contribute to a PC biomarker panel. In conclusion, we report the development and validation of a new method for fluorescence quantification of proteins in archived tissues and its application to archived specimens for an evaluation of β-catenin expression as a biomarker for PC.

Original languageEnglish (US)
Pages (from-to)1371-1381
Number of pages11
JournalCancer Epidemiology Biomarkers and Prevention
Volume16
Issue number7
DOIs
StatePublished - Jul 1 2007

Fingerprint

Catenins
Optical Imaging
Tumor Biomarkers
Prostate
Prostatic Neoplasms
Proteins
Proteomics
Formaldehyde
Fluorescence
Confidence Intervals
Protein Array Analysis
Human Genome
Proteome
ROC Curve
Epitopes
Early Diagnosis
Cross-Sectional Studies
Biomarkers
Biopsy
Antibodies

ASJC Scopus subject areas

  • Epidemiology
  • Oncology

Cite this

Quantitative fluorescence imaging analysis for cancer biomarker discovery : Application to β-catenin in archived prostate specimens. / Huang, Dali; Casale, George P; Tian, Jun; Wehbi, Nizar K; Abrahams, Neil A.; Kaleem, Zahid; Smith, Lynette M; Johansson, Sonny L.; Elkahwaji, Johny E.; Hemstreet, George P.

In: Cancer Epidemiology Biomarkers and Prevention, Vol. 16, No. 7, 01.07.2007, p. 1371-1381.

Research output: Contribution to journalArticle

Huang, Dali ; Casale, George P ; Tian, Jun ; Wehbi, Nizar K ; Abrahams, Neil A. ; Kaleem, Zahid ; Smith, Lynette M ; Johansson, Sonny L. ; Elkahwaji, Johny E. ; Hemstreet, George P. / Quantitative fluorescence imaging analysis for cancer biomarker discovery : Application to β-catenin in archived prostate specimens. In: Cancer Epidemiology Biomarkers and Prevention. 2007 ; Vol. 16, No. 7. pp. 1371-1381.
@article{3c8b34c0ad4e4048a4283e5445936090,
title = "Quantitative fluorescence imaging analysis for cancer biomarker discovery: Application to β-catenin in archived prostate specimens",
abstract = "The surprising disparity between the number of protein-encoding genes (∼30,000) in the human genome and the number of proteins (∼300,000) in the human proteome has inspired the development of translational proteomics aimed at protein expression profiling of disease states. Translational proteomics, which offers the promise of early disease detection and individualized therapy, requires new methods for the analysis of clinical specimens. We have developed quantitative flourescence imaging analysis (QFIA) for accurate, reproducible quantification of proteins in slide-mounted tissues. The method has been validated for the analysis of β-catenin in archived prostate specimens fixed in formalin. QFIA takes advantage of the linearity of fluorescence antibody signaling for tissue epitope content, a feature validated for β-catenin in methacarn-fixed prostate specimens analyzed by reverse-phase protein array analysis and QFIA (r = 0.97). QFIA of β-catenin in formaldehyde-fixed tissues correlated directly with β-catenin content (r = 0.86). Application of QFIA in a cross-sectional study of biopsies from 42 prostate cancer (PC) cases and 42 matched controls identified β-catenin as a potential field marker for PC. Receiver operating characteristic plots revealed that β-catenin expression in the normal-appearing acini of cancerous glands identified 42{\%} (95{\%} confidence intervals, 26-57{\%}) of cancer cases, with 88{\%} (95{\%} confidence intervals, 80-96{\%}) specificity. The marker may contribute to a PC biomarker panel. In conclusion, we report the development and validation of a new method for fluorescence quantification of proteins in archived tissues and its application to archived specimens for an evaluation of β-catenin expression as a biomarker for PC.",
author = "Dali Huang and Casale, {George P} and Jun Tian and Wehbi, {Nizar K} and Abrahams, {Neil A.} and Zahid Kaleem and Smith, {Lynette M} and Johansson, {Sonny L.} and Elkahwaji, {Johny E.} and Hemstreet, {George P.}",
year = "2007",
month = "7",
day = "1",
doi = "10.1158/1055-9965.EPI-06-0718",
language = "English (US)",
volume = "16",
pages = "1371--1381",
journal = "Cancer Epidemiology Biomarkers and Prevention",
issn = "1055-9965",
publisher = "American Association for Cancer Research Inc.",
number = "7",

}

TY - JOUR

T1 - Quantitative fluorescence imaging analysis for cancer biomarker discovery

T2 - Application to β-catenin in archived prostate specimens

AU - Huang, Dali

AU - Casale, George P

AU - Tian, Jun

AU - Wehbi, Nizar K

AU - Abrahams, Neil A.

AU - Kaleem, Zahid

AU - Smith, Lynette M

AU - Johansson, Sonny L.

AU - Elkahwaji, Johny E.

AU - Hemstreet, George P.

PY - 2007/7/1

Y1 - 2007/7/1

N2 - The surprising disparity between the number of protein-encoding genes (∼30,000) in the human genome and the number of proteins (∼300,000) in the human proteome has inspired the development of translational proteomics aimed at protein expression profiling of disease states. Translational proteomics, which offers the promise of early disease detection and individualized therapy, requires new methods for the analysis of clinical specimens. We have developed quantitative flourescence imaging analysis (QFIA) for accurate, reproducible quantification of proteins in slide-mounted tissues. The method has been validated for the analysis of β-catenin in archived prostate specimens fixed in formalin. QFIA takes advantage of the linearity of fluorescence antibody signaling for tissue epitope content, a feature validated for β-catenin in methacarn-fixed prostate specimens analyzed by reverse-phase protein array analysis and QFIA (r = 0.97). QFIA of β-catenin in formaldehyde-fixed tissues correlated directly with β-catenin content (r = 0.86). Application of QFIA in a cross-sectional study of biopsies from 42 prostate cancer (PC) cases and 42 matched controls identified β-catenin as a potential field marker for PC. Receiver operating characteristic plots revealed that β-catenin expression in the normal-appearing acini of cancerous glands identified 42% (95% confidence intervals, 26-57%) of cancer cases, with 88% (95% confidence intervals, 80-96%) specificity. The marker may contribute to a PC biomarker panel. In conclusion, we report the development and validation of a new method for fluorescence quantification of proteins in archived tissues and its application to archived specimens for an evaluation of β-catenin expression as a biomarker for PC.

AB - The surprising disparity between the number of protein-encoding genes (∼30,000) in the human genome and the number of proteins (∼300,000) in the human proteome has inspired the development of translational proteomics aimed at protein expression profiling of disease states. Translational proteomics, which offers the promise of early disease detection and individualized therapy, requires new methods for the analysis of clinical specimens. We have developed quantitative flourescence imaging analysis (QFIA) for accurate, reproducible quantification of proteins in slide-mounted tissues. The method has been validated for the analysis of β-catenin in archived prostate specimens fixed in formalin. QFIA takes advantage of the linearity of fluorescence antibody signaling for tissue epitope content, a feature validated for β-catenin in methacarn-fixed prostate specimens analyzed by reverse-phase protein array analysis and QFIA (r = 0.97). QFIA of β-catenin in formaldehyde-fixed tissues correlated directly with β-catenin content (r = 0.86). Application of QFIA in a cross-sectional study of biopsies from 42 prostate cancer (PC) cases and 42 matched controls identified β-catenin as a potential field marker for PC. Receiver operating characteristic plots revealed that β-catenin expression in the normal-appearing acini of cancerous glands identified 42% (95% confidence intervals, 26-57%) of cancer cases, with 88% (95% confidence intervals, 80-96%) specificity. The marker may contribute to a PC biomarker panel. In conclusion, we report the development and validation of a new method for fluorescence quantification of proteins in archived tissues and its application to archived specimens for an evaluation of β-catenin expression as a biomarker for PC.

UR - http://www.scopus.com/inward/record.url?scp=34447512839&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34447512839&partnerID=8YFLogxK

U2 - 10.1158/1055-9965.EPI-06-0718

DO - 10.1158/1055-9965.EPI-06-0718

M3 - Article

VL - 16

SP - 1371

EP - 1381

JO - Cancer Epidemiology Biomarkers and Prevention

JF - Cancer Epidemiology Biomarkers and Prevention

SN - 1055-9965

IS - 7

ER -